"SALK" HIV-1 IMMUNOGEN MANUFACTURING, PROTOCOL CONCERNS RAISED BY FDA; AGENCY SEES NO SIGNIFICANT DIFFERENCE VERSUS PLACEBO FOR MOST SURROGATE MARKERS
Immunization Products Limited's preliminary trials of the HIV-1 immunogen show few significant differences over placebo, according to FDA's reading of the data, Center for Biologics Evaluation & Research Senior Investigator Ira Berkower, MD/PhD, told FDA's Vaccines & Related Biological Products Advisory Committee at its Jan. 26 meeting.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth